Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema in 1206 obese ... weight loss of 13.7% vs 3.4% with placebo. Notably, at the ...

which is a phase 3 cardiovascular outcomes trial compared once-weekly CagriSema with placebo in adults with established cardiovascular disease with or without type 2 diabetes, and REDEFINE 4, an ...

Topline results from the REDEFINE-4 trial in the second half of the year when Novo Nordisk is testing CagriSema directly against Eli Lilly’s tirzepatide. Regulatory submission for FDA approval ...

Despite the positive results, Novo Nordisk’s shares tumbled 9.4% on Monday as the 15.7% weight loss observed in obese and T2D ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

"We're not sure that the CagriSema is best in class." However, an upcoming REDEFINE-4 study, due for release in early 2026, could provide further color on the drug's efficacy over an extended ...